Theravance Biopharma Inc
TBPH · Price history
Price chart data is not currently available.
Company & revenue
About Theravance Biopharma Inc
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.
How they make money
Theravance Biopharma generates revenue primarily through a collaboration agreement with Viatris for the commercialization of YUPELRI, receiving a share of net sales and potential sales-based milestones. Additionally, the company earns royalty and milestone income from licensing arrangements, such as those related to the TRELEGY respiratory product, and manages its capital through marketable securities.
Products & services
The company's primary commercial product is YUPELRI (revefenacin), a long-acting muscarinic antagonist indicated for the treatment of chronic obstructive pulmonary disease (COPD).
Brands & revenue mix
A long-acting muscarinic antagonist for the treatment of COPD.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Customer types
- Hospital channelSource
Disclosed major customers
- ViatrisSource
Customer concentration
The company's revenue is highly concentrated due to its reliance on the Viatris collaboration for YUPELRI and royalty streams from partners like Royalty Pharma, as disclosed in the 2025 annual report.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production and supply of its pharmaceutical products; specific supplier names are not disclosed.Source
Business relationships & partnerships
Strengths
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Quarterly revenue fell 20.9% versus the same quarter last year.
Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
Quarterly EPS turned negative at -0.11 versus 1.08 a year earlier.
Separate recurring operating losses from noncash or one-time charges, and check cash flow rather than interpreting negative EPS as a cash-outflow amount.
Quarterly net income turned from a profit to a loss versus the same quarter last year.
Identify the causes in the interim report and distinguish operating cash use from accounting charges. Prior profitability is not a guarantee of recovery.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
55
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
51
Fair
Financial Strength
44
Business Quality / Moat
61
Management
80
Growth Quality
40
Risk / Durability
10
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
60
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
54/100
Building Historical Record
Model Score 54/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Valuation scores attractively
- •Recent buyback activity is present
- •Debt service risk
- •M&A headline · Aug 11, 2026
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for TBPH
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving TBPH's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •Is TBPH's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is TBPH likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is TBPH's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of TBPH's score?
Essential Investment Snapshot
Wall Street Score
55
Opportunity Score
60
Market Cap
$884.2M
P/E Ratio
16.0
EPS
$1.06
52-Week High
$21.03
52-Week Low
$13.08
Beta
0.17
Intrinsic Value
$40.96
Analyst Target
$17.00
Shares Outstanding
51.5M
Total Revenue
$104.3M
Total Debt
$38.6M
Dividend
No current dividend
Liquidation Value / Share
$5.62
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for TBPH
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Debt service risk
Interest coverage is low (~-5.4x). Earnings may be strained to cover interest expense.
M&A headline · Aug 11, 2026
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Zacks Investment ResearchCommunity Sentiment
0 active · 0 total callsNo personal call yet on TBPH.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong balance sheet with significant cash and marketable securities.
- +Durability of the YUPELRI commercial asset.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party collaborators and contract manufacturers.
- −Risks associated with clinical development and regulatory approval processes.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
55
Oct 1, 2026
Change
Unchanged
Current Score
55
Oct 22, 2026
Category Changes
TBPH score was unchanged.
Projected Score
Projected Score
45
Projected Change
-10.2 points
Preliminary comparable-period financial changes suggest decline of approximately 10.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$17.03
Model Intrinsic Value
$40.96
Difference
−$23.93
-58.4% vs IV
Margin of Safety
58.4%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +66.9%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104.3M | $107.5M | $64.4M | $57.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | -$15.0M | $5.5M | $37.6M | $40.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $119.3M | $101.9M | $26.7M | $16.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $26.0M | $37.4M | $38.0M | $46.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $105.5M | $73.7M | $69.2M | $70.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $121.8M | $115.2M | $73.7M | $72.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $70.1M | $137.2M | -$38.5M | -$49.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$2.5M | -$13.2M | -$46.9M | -$56.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $1.2M | $2.5M | $2.5M | $2.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $58.9M | $129.2M | -$44.6M | -$49.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $5.1M | $23.4M | $11.8M | $5.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $53.8M | $105.9M | -$56.4M | -$55.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $1.07 | $2.10 | $-1.15 | $-1.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 51.67M | 50.32M | 48.85M | 55.30M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 51.67M | 51.51M | 48.85M | 55.30M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$20.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.11
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-17.0%
Cash Change
-22.0%
Margin Change
-237.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included debt levels. Pressure indicators included revenue growth, EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 20.9%. EPS declined 110.2%. Cash declined 22.0%. Total debt declined 17.0%. Net income margin declined by 237.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Financial Analysis: Chugai Pharmaceutical (OTCMKTS:CHGCY) & Theravance Biopharma (NASDAQ:TBPH)
CASI Pharmaceuticals (NASDAQ:CASI) & Theravance Biopharma (NASDAQ:TBPH) Financial Analysis
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head Contrast
Rumor Mill · TBPH
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial